Selective Omission of Sentinel Lymph Node Biopsy in Mastectomy for Ductal Carcinoma in Situ: Identifying Eligible Candidates

Gangnam Severance Hospital385 enrolled

Overview

This study aimed to assess the prevalence of upgrade to invasive breast cancer and axillary lymph node metastasis in patients who were diagnosed with DCIS on biopsy and subsequently underwent mastectomy with axillary surgery to establish the need for SLNB. Furthermore, we explored the clinicopathologic features related to the upgrade to invasive breast cancer and axillary lymph node metastasis.

Study Type

OBSERVATIONAL

Enrollment

385

Conditions

Ductal Carcinoma in Situ

Interventions

Mastectomy with sentinel lymph node biopsyPROCEDURE

Eligibility

Sex: FEMALEMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Women diagnosed with DCIS in preoperative biopsy samples obtained by core needle biopsy, vacuum-assisted breast biopsy, or excisional biopsy 2. Women underwent curative surgery for DCIS Exclusion Criteria: 1. Patients who received breast-conserving surgery 2. Patients who had concurrent contralateral invasive breast cancer 3. Patients who were in case of ipsilateral breast tumor recurrence 4. Patients whose invasiveness was uncertain in the biopsy samples

Outcomes

Primary Outcomes

Axillary lymph node metastasis rate

Our primary objective was to identify the axillary lymph node metastasis rate in patients with DCIS at diagnosis who underwent mastectomy with axillary surgery.

Time frame: up to 2 weeks after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.